Phase IB study of sorafenib and evofosfamide in patients with advanced hepatocellular and renal cell carcinomas (NCCTG N1135, Alliance).

Aged Antineoplastic Combined Chemotherapy Protocols / administration & dosage Carcinoma, Hepatocellular / drug therapy Carcinoma, Renal Cell / drug therapy Female Humans Kidney Neoplasms / drug therapy Liver Neoplasms / drug therapy Male Maximum Tolerated Dose Middle Aged Nitroimidazoles / administration & dosage Phosphoramide Mustards / administration & dosage Sorafenib / administration & dosage Treatment Outcome
Evofosfamide Hepatocellular cancer Hypoxia activated pro-drug (HAP)

Journal

Investigational new drugs
ISSN: 1573-0646
Titre abrégé: Invest New Drugs
Pays: United States
ID NLM: 8309330

Informations de publication

Date de publication:
08 2021
Historique:
received: 18 02 2021
accepted: 22 02 2021
pubmed: 2 3 2021
medline: 3 2 2022
entrez: 1 3 2021
Statut: ppublish

Résumé

Background Sorafenib (Sor) remains a first-line option for hepatocellular carcinoma (HCC) or refractory renal cell carcinomas (RCC). PLC/PRF/5 HCC model showed upregulation of hypoxia with enhanced efficacy when Sor is combined with hypoxia-activated prodrug evofosfamide (Evo). Methods This phase IB 3 + 3 design investigated 3 Evo dose levels (240, 340, 480 mg/m

Identifiants

DOI: 10.1007/s10637-021-01090-w PMID: 33646489 PMC: PMC8282689
pubmed: 33646489
doi: 10.1007/s10637-021-01090-w
pii: 10.1007/s10637-021-01090-w
pmc: PMC8282689
mid: NIHMS1692141
doi:

Substances chimiques

Nitroimidazoles 0
Phosphoramide Mustards 0
TH 302 0
Sorafenib 9ZOQ3TZI87

Types de publication

Clinical Trial, Phase I Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1072-1080

Subventions

Organisme : NCI NIH HHS
ID : U10 CA180821
Pays : United States
Organisme : NCI NIH HHS
ID : K12 CA090628
Pays : United States
Organisme : NCI NIH HHS
ID : UG1 CA232760
Pays : United States
Organisme : NCI NIH HHS
ID : DP2 CA195764
Pays : United States
Organisme : NCI NIH HHS
ID : U10 CA180882
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA015083
Pays : United States
Organisme : NCI NIH HHS
ID : UG1 CA233180
Pays : United States

Informations de copyright

© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC part of Springer Nature.

Références

Cells. 2019 Jul 13;8(7):
pubmed: 31337055
Clin Cancer Res. 2006 Dec 1;12(23):6910-9
pubmed: 17145808
Lancet Oncol. 2020 Jan;21(1):95-104
pubmed: 31810797
Oncology. 2011;80(1-2):50-6
pubmed: 21625179
N Engl J Med. 2020 May 14;382(20):1894-1905
pubmed: 32402160
Clin Cancer Res. 2012 Feb 1;18(3):758-70
pubmed: 22184053
Nat Rev Cancer. 2011 Jun;11(6):393-410
pubmed: 21606941
Cancer Metab. 2013 Feb 04;1(1):8
pubmed: 24280138
J Clin Oncol. 2010 Jun 20;28(18):2989-95
pubmed: 20479425
J Clin Oncol. 2014 Feb 10;32(5):458-64
pubmed: 24395863
JAMA Oncol. 2017 Dec 1;3(12):1683-1691
pubmed: 28983565
N Engl J Med. 2008 Jul 24;359(4):378-90
pubmed: 18650514
Lancet Oncol. 2019 Feb;20(2):282-296
pubmed: 30665869
Nat Rev Cancer. 2006 Aug;6(8):583-92
pubmed: 16862189
Cell Metab. 2012 Dec 5;16(6):751-64
pubmed: 23177934
Lancet Oncol. 2009 Jan;10(1):25-34
pubmed: 19095497
Int J Cancer. 2015 Mar 1;136(5):E359-86
pubmed: 25220842
J Clin Oncol. 2014 Oct 10;32(29):3299-306
pubmed: 25185097
N Engl J Med. 2019 Mar 21;380(12):1116-1127
pubmed: 30779529
CA Cancer J Clin. 2019 Jan;69(1):7-34
pubmed: 30620402
J Clin Oncol. 2020 Jan 20;38(3):193-202
pubmed: 31790344
N Engl J Med. 2018 Jul 05;379(1):54-63
pubmed: 29972759
J Cell Mol Med. 2010 Mar;14(3):496-503
pubmed: 20082654
N Engl J Med. 2018 Apr 05;378(14):1277-1290
pubmed: 29562145
Lancet Oncol. 2017 Aug;18(8):1089-1103
pubmed: 28651927
Nat Rev Cancer. 2008 Nov;8(11):865-73
pubmed: 18923434
N Engl J Med. 2019 Mar 21;380(12):1103-1115
pubmed: 30779531
Cancer Med. 2016 Mar;5(3):534-45
pubmed: 26749324
J Clin Oncol. 2015 May 1;33(13):1475-81
pubmed: 25512461
Cancer Commun (Lond). 2018 May 3;38(1):15
pubmed: 29764490
J Med Chem. 2008 Apr 24;51(8):2412-20
pubmed: 18257544
Mol Cell Biol. 2004 Apr;24(7):2875-89
pubmed: 15024076
Pharmacol Ther. 2016 Aug;164:152-69
pubmed: 27139518
Cancer Chemother Pharmacol. 2017 Mar;79(3):611-619
pubmed: 28238078
Free Radic Biol Med. 2012 Aug 1;53(3):421-36
pubmed: 22580150
Clin Cancer Res. 2011 May 1;17(9):2997-3004
pubmed: 21415214
Cancer Metastasis Rev. 2007 Jun;26(2):311-7
pubmed: 17404691
J Natl Cancer Inst. 2001 Feb 21;93(4):266-76
pubmed: 11181773

Auteurs

Nguyen H Tran (NH)

Division of Oncology, Department of Medicine, Mayo Clinic, Rochester, MN, USA.

Nathan R Foster (NR)

Alliance Statistics and Data Center, Mayo Clinic, Rochester, MN, USA.

Amit Mahipal (A)

Division of Oncology, Department of Medicine, Mayo Clinic, Rochester, MN, USA.

Thomas Byrne (T)

Division of Gastroenterology and Hepatology, Mayo Clinic, Phoenix, AZ, USA.

Joleen Hubbard (J)

Division of Oncology, Department of Medicine, Mayo Clinic, Rochester, MN, USA.

Alvin Silva (A)

Department of Radiology, Mayo Clinic, AZ, Scottsdale, USA.

Kabir Mody (K)

Division of Oncology, Department of Medicine, Mayo Clinic, Jacksonville, FL, USA.

Steven Alberts (S)

Division of Oncology, Department of Medicine, Mayo Clinic, Rochester, MN, USA.

Mitesh J Borad (MJ)

Mayo Clinic Cancer Center, Mayo Clinic, Phoenix, AZ, USA. borad.mitesh@mayo.edu.
Division of Oncology, Department of Medicine, Mayo Clinic, Scottsdale, AZ, USA. borad.mitesh@mayo.edu.
Center for Individualized Medicine, Mayo Clinic, Rochester, MN, USA. borad.mitesh@mayo.edu.
Department of Molecular Medicine, Mayo Clinic, Rochester, MN, USA. borad.mitesh@mayo.edu.
Director - Precision Cancer Therapeutics Program, Mayo Clinic Center for Individualized Medicine (CIM) Program Leader - Gene and Virus Therapy Program, Mayo Clinic Cancer Center, 5777 E Mayo Blvd, Phoenix, AZ, 85254, USA. borad.mitesh@mayo.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Sujet âgé › Phase IB study of sorafenib and evofosfamide...
questionsmedicales.fr › Thérapeutique › Traitement médicamenteux › Association de médicaments › Protocoles de polychimiothérapie antinéoplasique › Phase IB study of sorafenib and evofosfamide...
questionsmedicales.fr › Maladies de l'appareil digestif › Maladies du foie › Tumeurs du foie › Carcinome hépatocellulaire › Phase IB study of sorafenib and evofosfamide...
questionsmedicales.fr › Maladies urogénitales › Maladies urologiques › Tumeurs urologiques › Tumeurs du rein › Néphrocarcinome › Phase IB study of sorafenib and evofosfamide...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Phase IB study of sorafenib and evofosfamide...
questionsmedicales.fr › Maladies urogénitales › Maladies urologiques › Tumeurs urologiques › Tumeurs du rein › Phase IB study of sorafenib and evofosfamide...
questionsmedicales.fr › Maladies de l'appareil digestif › Maladies du foie › Tumeurs du foie › Phase IB study of sorafenib and evofosfamide...
questionsmedicales.fr › Phénomènes physiologiques › Phénomènes pharmacologiques et toxicologiques › Phénomènes toxicologiques › Dose maximale tolérée › Phase IB study of sorafenib and evofosfamide...
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Adulte d'âge moyen › Phase IB study of sorafenib and evofosfamide...
questionsmedicales.fr › Composés hétérocycliques › Composés hétéromonocycliques › Azoles › Imidazoles › Nitroimidazoles › Phase IB study of sorafenib and evofosfamide...
questionsmedicales.fr › Composés chimiques organiques › Composés organiques du phosphore › Phosphoramides › Moutardes phosphoramide › Phase IB study of sorafenib and evofosfamide...
questionsmedicales.fr › Composés hétérocycliques › Composés hétéromonocycliques › Pyridines › Acides nicotiniques › Nicotinamide › Sorafénib › Phase IB study of sorafenib and evofosfamide...
questionsmedicales.fr › Qualité, accès, évaluation des soins de santé › Qualité des soins de santé › Mécanismes d'évaluation des soins de santé › Évaluation des résultats et des processus en soins de santé › Évaluation de résultat (soins) › Résultat thérapeutique › Phase IB study of sorafenib and evofosfamide...